Sequential changes in coagulation and platelet function following femorotibial bypass.
Twenty-four patients who received no antiplatelet medications and underwent femorotibial bypass grafting (nine vein, 12 polytetrafluoroethylene [PTFE], and three composite PTFE-vein) had serial measurements taken of their platelet function and coagulation. The concentration of collagen required to produce half-maximal platelet aggregation (Kd), the platelet aggregation ratio, antithrombin III, factor VIII-related antigen, and fibrinolytic activity (platelet-rich plasma) was measured preoperatively and 3 and 7 days after surgery. Before surgery eight patients exhibited an increase of platelet reactivity to collagen. Following femorotibial bypass grafting, the mean preoperative Kd of 0.52 +/- 0.37 microgram/ml fell to 0.34 +/- 0.35 microgram/ml on the third postoperative day (P less than 0.001) and returned to 0.41 +/- 0.72 microgram/ml on day 7. Factor VIII-related antigen increased from a mean preoperative value of 248 +/- 29% of normal activity to a mean of 360 +/- 96% on postoperative day 3 (p less than 0.01) and further increased to 428 +/- 78% on day 7 (p less than 0.01). Fourteen patients had antithrombin III measurements taken, and their levels also fell on the third postoperative day (110 +/- 5.7% to 71 +/- 6.5%; p less than 0.001). No significant changes in fibrinolytic activity were noted. Persistent platelet reactivity was found in seven patients beyond the seventh postoperative day. After administration of 325 mg of aspirin, the abnormal platelet reactivity ceased. Increased platelet reactivity to collagen, factor VIII-related antigen, and a decrease in the antithrombin III level are indicative of a hypercoagulable state in these patients.(ABSTRACT TRUNCATED AT 250 WORDS)
D000941:Antigens / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D003094:Collagen / Q000494:pharmacology; D005169:Factor VIII / Q000032:analysis / Q000276:immunology; D005268:Femoral Vein / Q000601:surgery*; D005342:Fibrinolysis; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008297:Male; D010974:Platelet Aggregation; D014841:von Willebrand Factor
D000941:Antigens; D014841:von Willebrand Factor; D000990:Antithrombin III; D005169:Factor VIII; D006493:Heparin; D003094:Collagen